Neurocrine Biosciences, Inc.: Commercial Expansion & Market Penetration Underpinning Our ‘Outperform’ Rating! 

Neurocrine Biosciences has presented its third-quarter 2024 results, highlighting both achievements and ongoing strategic initiatives. Under the new leadership of CEO Kyle Gano, the company is focusing on strengthening its position as a leading neuroscience organization. Its revenue growth has been particularly driven by the performance of its drug INGREZZA, with an impressive $613 million in sales this quarter, translating to 25% year-over-year growth. This success is attributed to strong patient demand and the application of tardive dyskinesia (TD) and Huntington’s disease chorea indications. INGREZZA’s market potential is underscored by the fact that a majority of patients with tardive dyskinesia remain untreated by VMAT2 inhibitors, leaving substantial room for
growth.